Cocos Nucifera Endocarp Extract Exhibits Anti-diabetic and Antilipidemic Activities in Diabetic Rat Model

Document Type : Original Article


1 Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka, Bangladesh

2 Department of Pharmacy, Jagannath University, Dhaka, Bangladesh

3 Department of Pharmacy, Chittagong University, Chittagong, Bangladesh

4 Department of Pharmacology, Bangladesh University of Health Sciences, Dhaka, Bangladesh


Background and aim: The fruits of Cocos nucifera have long been used in traditional medicine as anti-inflammatory, antimicrobial, antiparasitic, anticancer, and cardiotonic. This study aimed to evaluate the anti-diabetic and antilipidemic activities in the diabetic rat model.
Material and methods: Cocos nucifera endocarp was extracted with Methanol and then fractionated with different solvents, namely h-hexane, Chloroform, and ethyl acetate. A total of 30 Streptozotocin-induced diabetic rats were used in six experimental groups. All the animals were treated for 14 days period. The measured outcomes were fasting blood sugar (FBS), lipid profiles, acute hypoglycaemic effects, and changes in body weights. Antioxidative studies and phytochemical screening were also performed.
Results: A significant hypoglycemic effect was found in the group treated with ethyl acetate fractions (6.33 ± 0.32 mmol/L, p<0.05) when compared to placebo (7.85±0.38 mmol/L). After a glucose load, the same fraction also showed a significant antihyperglycemic effect within 75 minutes of treatment. Both ethyl acetate and chloroform fractions reduced the baseline serum cholesterol and triglyceride levels. However, no significant change in body weight was reported in any treatment groups. In the DPPH free radical scavenging assay, the methanolic fraction and ethyl acetate fractions showed notable free radical scavenging activity with IC50 value 32.31 μg/ml and 27.55 respectively, compared to standard Tert-Butyl-1-hydroxytolune (23.92 μg/ml), indicating potential antioxidative properties.
Conclusions: Cocos nucifera endocarp showed promising anti-diabetic and antilipidemic properties. The ethyl acetate soluble fraction might be further explored to isolate active medicinal compounds in drug discovery.


Main Subjects

[1]  Sile I, Romane E, Reinsone S, Maurina B, Tirzite D, Dambrova M. Medicinal plants and their uses recorded in the Archives of Latvian Folklore from the 19th century. Journal of Ethnopharmacology. 2020;249:112378.
[2]  Eder J, Herrling PL. Trends in modern drug discovery. New Approaches to Drug Discovery. 2015:3-22.
[3]  Tian XY, Liu L. Drug discovery enters a new era with multi-target intervention strategy. Chinese journal of integrative medicine. 2012;18(7):539-42.
[4]  International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021. Available at: (Accessed on 16 December 2021).
[5]  Chukwuma CI, Matsabisa MG, Ibrahim MA, Erukainure OL, Chabalala MH, Islam MS. Medicinal plants with concomitant anti-diabetic and anti-hypertensive effects as potential sources of dual acting therapies against diabetes and hypertension: a review. Journal of ethnopharmacology. 2019;235:329-60.
[6]  Roopan SM, Elango G. Exploitation of Cocos nucifera a non-food toward the biological and nanobiotechnology field. Industrial Crops and Products. 2015;67:130-6.
[7]  Singla RK, Dubey AK. Phytochemical profiling, GC-MS analysis and α-amylase inhibitory potential of ethanolic extract of Cocos nucifera Linn. Endocarp. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 2019;19(4):419-42.
[8] Singla RK, Ali M, Kamal MA, Dubey AK. Isolation and characterization of nuciferoic acid, a novel keto fatty acid with hyaluronidase inhibitory activity from Cocos nucifera Linn. endocarp. Current Topics in Medicinal Chemistry. 2018;18(27):2367-78.
[9]  Bankar GR, Nayak PG, Bansal P, Paul P, Pai KS, Singla RK, et al. Vasorelaxant and antihypertensive effect of Cocos nucifera Linn. endocarp on isolated rat thoracic aorta and DOCA salt-induced hypertensive rats. Journal of ethnopharmacology. 2011;134(1):50-4.
[10] VanWagenen BC, Larsen R, Cardellina JH, Randazzo D, Lidert ZC, Swithenbank C. Ulosantoin, a potent insecticide from the sponge Ulosa ruetzleri. The Journal of Organic Chemistry. 1993;58(2):335-7.
[11] Barham D, Trinder P. An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst. 1972;97(1151):142-5.
[12] Trinder P. Glucose assay: a colorimetric enzyme-kinetic method assay. Ann Clin Biochem. 1969;6:24.
[13] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972;18(6):499-02.
[14] Kratzsch J, Ackermann W, Keilacker H, Besch W, Keller E. A sensitive sandwich enzyme immunoassay for measurement of insulin on microtiter plates. Experimental and Clinical Endocrinology & Diabetes. 1990;95(02):229-36. DOI: 10.1055/s-0029-1210957.
[15] Muriel P, Deheza R. Fibrosis and glycogen stores depletion induced by prolonged biliary obstruction in the rat are ameliorated by metadoxine. Liver international. 2003;23(4):262-8.
[16] Bonner-Weir S, Trent DF, Honey RN, Weir GC. Responses of neonatal rat islets to streptozotocin: limited B-cell regeneration and hyperglycemia. Diabetes. 1981;30(1):64-9.
[17] Siddiqui S, Verma A, Rather AA, Jabeen F, Meghvansi MK. Preliminary phytochemicals analysis of some important medicinal and aromatic plants. Advances in biological research. 2009;3(5-6):188-95.
[18] Blois MS. Antioxidant determinations by the use of a stable free radical. Nature. 1958;181(4617):1199-200.
[19] Akbarzadeh A, Norouzian D, Mehrabi MR, Jamshidi SH, Farhangi A, Verdi AA, et al. Induction of diabetes by streptozotocin in rats. Indian Journal of Clinical Biochemistry. 2007;22(2):60-4.
[20] Naveen J, Baskaran V. Antidiabetic plant-derived nutraceuticals: a critical review. European journal of nutrition. 2018;57(4):1275-99.
[21] Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiological reviews. 2018;98(4):2133-223.
[22] Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S, et al. The role of inflammation in diabetes: current concepts and future perspectives. European cardiology review. 2019;14(1):50-9. doi: 10.15420/ecr.2018.33.1.
[23] Ticar BF, Rohmah Z, Mussatto SI, Lim JM, Park S, Choi BD. Hyaluronidase-inhibitory activities of glycosaminoglycans from Liparis tessellatus eggs. Carbohydrate polymers. 2017;161:16-20.
[24] Luc K, Schramm-Luc A, Guzik TJ, Mikolajczyk TP. Oxidative stress and inflammatory markers in prediabetes and diabetes. J. Physiol. Pharmacol. 2019;70(6):809-24.
[25] Parikh NH, Parikh PK, Kothari C. Indigenous plant medicines for health care: treatment of Diabetes mellitus and hyperlipidemia. Chinese journal of natural medicines. 2014;12(5):335-44.
[26] Padumadasa C, Dharmadana D, Abeysekera A, Thammitiyagodage M. In vitro antioxidant, anti-inflammatory and anticancer activities of ethyl acetate soluble proanthocyanidins of the inflorescence of Cocos nucifera L. BMC complementary and alternative medicine. 2016;16(1):1-6.
[27] Kim Y, Keogh JB. Clifton. Polyphenols and glycemic control. Nutrients. 2016;8:E17. doi: 10.3390/nu8010017.
[28] Alam F, Shafique Z, Amjad ST, Bin Asad MH. Enzymes inhibitors from natural sources with antidiabetic activity: A review. Phytotherapy Research. 2019;33(1):41-54.
[29] Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, et al. Diabetes and lipid metabolism. Hormones. 2018;17(1):61-7.
[30] Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nature Reviews Cardiology. 2018;15(12):757-69.
[31] Cheng C, Li Z, Zhao X, Liao C, Quan J, Bode AM, et al. Natural alkaloid and polyphenol compounds targeting lipid metabolism: Treatment implications in metabolic diseases. European Journal of Pharmacology. 2020;870:172922.
Volume 4, Issue 1
March 2022
Pages 8-15
  • Receive Date: 09 December 2021
  • Revise Date: 22 January 2022
  • Accept Date: 05 February 2022
  • First Publish Date: 14 February 2022